Home : DrugWatch : Nexavar : News Articles

Nexavar - News Articles

UroToday - Login: patients with metastatic renal cell carcinoma (mRCC) undergoing treatment with the tyrosine kinase inhibitors (TKIs) sorafenib (So) or sunitinib (Su). ...
MD News - American Society of Clinical Oncology's Gastrointestinal Cancers Symposium, Jan. 20-22, 2011: In a phase II, multicenter study, Nicholas P. Campbell, MD, of the University of Chicago, and colleagues found that sorafenib was effective for patients with gastrointestinal stromal tumors (GIST) resistant to standard therapies. The investigators evaluated the effectiveness of sorafenib in 38 GIST ...
Complete response for advanced liver cancer during sorafenib therapy: Case Report: Similarly to other anti-angiogenic drugs employed in other tumour types, also sorafenib seldom induces the dimensional tumour shrinking usually observed with conventional cytotoxic drugs: data gathered from studies carried out with sorafenib and other competitors under development do not ...
Arch Dermatol -- Sign In Page: Sorafenib is a multikinase inhibitor approved for use in advanced renal cell and hepatocellular carcinomas. This oral agent is thought to inhibit tumor ...
Aveo Pharmaceuticals (NASDAQ: AVEO) Posts Large Volume Increase, Hits $14.34 – American Banking News: The TIVO-1 study is a randomized, controlled clinical trial of tivozanib compared to Nexavar (sorafenib) in advanced RCC patients who have not received any prior VEGF-targeted therapy. Nexavar is an oral VEGF receptor inhibitor approved for the treatment of RCC. Aveo Pharmaceuticals (NASDAQ: ...
Interesting Biotech Picks for 2011 - Seeking Alpha: The Company has one approved product, Nexavar® (sorafenib), which is an oral multiple kinase inhibitor (Figure 1 below) that targets proteins involved in both tumor cell proliferation and angiogenesis. (A protein kinase is a kinase enzyme that modifies other proteins by chemically ...
NCI Cancer Bulletin for January 25, 2011 - National Cancer Institute: The targeted therapy sorafenib (Nexavar) may be a treatment option for patients with gastrointestinal stromal tumors (GIST) whose cancers no longer respond to two FDA-approved therapies, researchers reported last week at the 2011 Gastrointestinal Cancers Symposium in San Francisco. In a ...
Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma: Systemic treatment consisted of sunitinib, sorafenib, temsirolimus or bevacizumab. The median PFS was 8.7 months (95% CI 5.1 - 12.3) and 11.4 months (95% CI 8.7 - 14.1) for BM-patients and non-BM-patients, respectively (p=0.232). The median overall survival for patients with and without BM ...
UroToday - Please Login - Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III TARGET - Abstract: 903 patients with advanced renal cell carcinoma (RCC) were randomized to sorafenib 400 mg bid or placebo. ELISAs were performed on samples collected at ...
UroToday - Please Login - Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients - Abstract: The objective of the present study was to document the treatment efficacy and safety of sorafenib in Japanese patients with advanced renal cellcarcinoma ...

Macmillan's Response To NICE Decision On Liver Cancer Drug: 'We are extremely disappointed that NICE has decided not to recommend sorafenib as a treatment for people with advanced liver cancer. 'It is a scandal that the only licensed drug proven to significantly prolong the lives of people with this ...
UroToday - Please Login - Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET - Abstract: The phase III Treatment Approaches in Renal cancer Global Evaluation Trial (TARGET) indicated that sorafenib is effective and well tolerated in advanced ...
UroToday - Please Login - Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation - Abstract: We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal ...
Battling cancer: Cipla has introduced Sorafenib Tosylate, a generic version of Bayer's advanced kidney cancer drug Nexavar, at about one-tenth the latter's price. ...
Owing to Increased Access to Medical Care and a Growing Drug-Treated Population, the Liver Cancer Drug Market in China Will Nearly Triple From $53 Million in 2009 to $144 Million in 2014 - MarketWatch: Chinese physicians report that Nexavar, Shandong Simcere Medgenn's Endostar and Chengdu Huasheng's Li Ka Ting are the main targeted therapies used for HCC in China. Additionally, by 2014, another targeted agent--brivanib (Bristol-Myers Squibb's BMS-582664)--is expected to be formally approved for HCC in ...
Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan - MarketWatch: FierceBiotech
Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a proteasome inhibitor, that is currently being ...
Melanoma Treatment Can Be Drawn From Gene Mutation | TopNews United States: After the failure of BRAF inhibitor sorafenib, for elevating the survival in melanoma patients last year, the role of the same has been doubted even more. The finding was published in the journal Science Translational Medicine. In the report, the reason for the ...
This Week in Science | The Daily Scan | GenomeWeb: "Signaling by the mutant proteins was resistant to the small-molecule inhibitor sorafenib, but sorafenib still inhibited the growth of tumors driven by the mutant protein," the authors write. In a news piece in Science this week, Michael Balter ...
Onyx Expects To File Myeloma Drug At FDA This Year: Onyx also expects to report results from a lung cancer trial of Nexavar, co-marketed with Bayer AG. "Most people expect the results to be negative," ...
Express.co.uk - Home of the Daily and Sunday Express | UK News :: Cash delay for cancer treatment could cost 16,000 lives: One of the groups suffering most are 400 liver cancer patients who have been denied the drug Nexavar to shrink their tumours and give them the chance of potentially life-saving surgery. ...

Looking for a Washington, DC Nexavar lawyer? Get in touch with one of our Washington, DC Nexavar lawyers now.

Pages: 1 2 Next

Need A Nexavar Attorney?

First Name Last Name Email Address State

Legal Issue

DrugWatch: Nexavar Click to select a Legal Issue

Has Your Health Been Negatively Affected?

Please Describe the Injury

close this window

Nexavar Information

Click to View Our Legal Resources

Looking for a Washington, DC Nexavar lawyer? Get in touch with one of our Washington, DC Nexavar lawyers now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120223-084043

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

DrugWatch: Nexavar Click to select a Legal Issue

Close (x)

Find Legal Help for Your Nexavar Case - Submit Your Information Below

Do you need legal assistance with your Nexavar case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * DrugWatch: Nexavar Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.